eli lilly glp-1 stock analysis Why Did Slide 6% Despite Strong Momentum? Eli Lilly Has Fallen 11%
Description
This medicine has a risk of thyroid C-cell tumors
(ii) Pathway-Aligned Endpoints
Big excitement
However, we did require that patients had a prescription fill of the GLP-1 RA and had a reason for discontinuation
But then Novo made a higher unsolicited offer, launching a bidding war
:max_bytes(150000):strip_icc()/LLY_2024-08-20_11-36-52-d41718ec53fc41e3b28fcbb59f487030.png)
Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of exenatide twice-daily
